Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: Data from the PATENT-2 open-label, randomised, long-term extension trial

The Lancet Respiratory Medicine

Volumn 4, Issue 5, 2016, Pages 361-371

  Ghofrani, Hossein Ardeschir ^a,b   Grimminger, Friedrich ^a   Grünig, Ekkehard ^c   Huang, Yigao ^d   Jansa, Pavel ^e   Jing, Zhi Cheng ^f   Kilpatrick, David ^g   Langleben, David ^h   Rosenkranz, Stephan ⁱ   Menezes, Flavia ^j   Fritsch, Arno ^k   Nikkho, Sylvia ^k   Humbert, Marc ^l,m,n  

^a JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^e CHARLES UNIVERSITY   (Czech Republic)

^f FUWAI HOSPITAL   (China)

^g UNIVERSITY OF TASMANIA   (Australia)

^h MCGILL UNIVERSITY   (Canada)

ⁱ UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^j Bayer HealthCare Pharmaceuticals   (Brazil)

^k BAYER PHARMA AG   (Germany)

^l UNIVERSITÉ PARIS SACLAY   (France)

^m BICÊTRE HOSPITAL   (France)

ⁿ CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ENDOTHELIN RECEPTOR ANTAGONIST; PLACEBO; PROSTANOID; RIOCIGUAT; ANTIHYPERTENSIVE AGENT; BRAIN NATRIURETIC PEPTIDE; PROSTAGLANDIN; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; COUGHING; DEATH; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DYSPNEA; EFFICACY PARAMETERS; FAINTNESS; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; HEADACHE; HEMOPTYSIS; HUMAN; HYPOTENSION; KAPLAN MEIER METHOD; LUNG HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; OPEN STUDY; OVERALL SURVIVAL; PERIPHERAL EDEMA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PULMONARY HYPERTENSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SURVIVAL; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; VOMITING; ADOLESCENT; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; MIDDLE AGED; PULMONARY ARTERY; TIME; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ENDOTHELIN RECEPTOR ANTAGONISTS; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PROSTAGLANDINS; PULMONARY ARTERY; PYRAZOLES; PYRIMIDINES; QUALITY OF LIFE; TIME; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84963607014     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(16)30019-4     Document Type: Article

References (35)

1. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 2015, 46:903-975.
2. McGoon MD, Benza RL, Escribano-Subias P, et al. Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol 2013, 62:D51-D59.
3. Taichman DB, Shin J, Hud L, et al. Health-related quality of life in patients with pulmonary arterial hypertension. Respir Res 2005, 6:92.
4. Farber HW, Miller DP, Poms AD, et al. Five-year outcomes of patients enrolled in the registry to evaluate early and long-term pulmonary arterial hypertension (PAH) disease management (REVEAL). Chest 2015, 148:1043-1054.
5. Humbert M, Sitbon O, Yaici A, et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J 2010, 36:549-555.
6. McLaughlin VV, Gaine SP, Howard LS, et al. Treatment goals of pulmonary hypertension. J Am Coll Cardiol 2013, 62:D73-D81.
7. Nickel N, Golpon H, Greer M, et al. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2012, 39:589-596.
8. Sitbon O, Benza RL, Badesch DB, et al. Validation of two predictive models for survival in pulmonary arterial hypertension. Eur Respir J 2015, 46:152-164.
9. Simonneau G, D'Armini AM, Ghofrani H-A, et al. Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial. Lancet Respir Med 2016, published online April 8. http://dx.doi.org/10.1016/S2213-2600(16)30022-4.
10. Stasch JP, Evgenov OV Soluble guanylate cyclase stimulators in pulmonary hypertension. Handb Exp Pharmacol 2013, 218:279-313.
11. Ghofrani H-A, Galiè N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013, 369:330-340.
12. Rubin LJ, Galiè N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). Eur Respir J 2015, 45:1303-1313.
13. Langleben D, Galie N, He J, et al. Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the phase III PATENT-1 study. J Heart Lung Transplant 2015, 34:338-347.
14. Gabler NB, French B, Strom BL, et al. Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials. Circulation 2012, 126:349-356.
15. Mathai SC, Puhan MA, Lam D, Wise RA The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 2012, 186:428-433.
16. Simonneau G, D'Armini AM, Ghofrani H-A, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). Eur Respir J 2015, 45:1293-1302.
17. Mathai SC, Odufowora O, Minai OA, et al. Health outcome assessment in pulmonary arterial hypertension patients treated with riociguat: 2-year results from the PATENT-2 long term extension study. Am J Respir Crit Care Med 2015, 191:A4777.
18. Benza RL, Seeger W, McLaughlin VV, et al. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension. J Heart Lung Transplant 2011, 30:1327-1333.
19. Provencher S, Sitbon O, Humbert M, Cabrol S, Jais X, Simonneau G Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J 2006, 27:589-595.
20. Farber HW, Miller DP, McGoon MD, Frost AE, Benton WW, Benza RL Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance. J Heart Lung Transplant 2015, 34:362-368.
21. Macchia A, Marchioli R, Marfisi R, et al. A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am Heart J 2007, 153:1037-1047.
22. Macchia A, Marchioli R, Tognoni G, et al. Systematic review of trials using vasodilators in pulmonary arterial hypertension: why a new approach is needed. Am Heart J 2010, 159:245-257.
23. Savarese G, Paolillo S, Costanzo P, et al. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. J Am Coll Cardiol 2012, 60:1192-1201.
24. Benza RL, Gomberg-Maitland M, Naeije R, Arneson CP, Lang IM Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials. J Heart Lung Transplant 2011, 30:982-989.
25. Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003, 41:2119-2125.
26. Barst RJ, Galiè N, Naeije R, et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J 2006, 28:1195-1203.
27. Oudiz RJ, Galiè N, Olschewski H, et al. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol 2009, 54:1971-1981.
28. Rubin LJ, Badesch DB, Fleming TR, et al. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: SUPER-2. Chest 2011, 140:1274-1283.
29. McLaughlin VV, Sitbon O, Badesch DB, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005, 25:244-249.
30. Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013, 369:809-818.
31. McLaughlin VV Survival in patients with pulmonary arterial hypertension treated with first-line bosentan. Eur J Clin Invest 2006, 36(suppl 3):10-15.
32. Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med 2015, 373:2522-2533.
33. Simonneau G, Channick RN, Delcroix M, et al. Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN. Eur Respir J 2015, 46:1711-1720.
34. Bayer Pharma AG Adempas: highlights of US prescribing information (accessed Nov 25, 2014). http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204819s000lbl.pdf.
35. Bayer Pharma AG Adempas (riociguat tablets): EU summary of product characteristics (accessed Nov 25, 2014). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002737/WC500165034.pdf.